title: [Trends in urology].
abstract: The systemic treatment of kidney cancers is promising regarding the first results of the inhibiting molecules of the angiogenesis. Projections in research are encouraging for more specific and sensitive markers of the prostate cancer. For this last the intermittent hormonotherapy improves the quality of life of the patients. The overweight control in infertility allows greater chances of giving birth. The morbidity of the kidney percutaneous surgery is decreased by the use of smaller tools. Reduction rate of reobstruction thanks to new manufactoring stents. The botulinic toxin for the hyperactive bladder refunded by the health insurances.
authors.affiliation: Service d'urologie, CHUV, Lausanne. Matieu.Uffer@chuv.ch
authors.forename: Matieu
authors.initials: M
authors.lastname: Uffer
authors.forename: Yves
authors.initials: Y
authors.lastname: Chollet
authors.forename: Céclie
authors.initials: C
authors.lastname: Cardinaux
authors.forename: Christoph
authors.initials: C
authors.lastname: Erling
authors.forename: Valentin
authors.initials: V
authors.lastname: Praz
authors.forename: Dursim
authors.initials: D
authors.lastname: Ramadani
authors.forename: Thomas
authors.initials: T
authors.lastname: Tawadros
authors.forename: Cédric
authors.initials: C
authors.lastname: Treutherdt
authors.forename: Marc
authors.initials: M
authors.lastname: Wisard
authors.forename: Yassin
authors.initials: Y
authors.lastname: Zarkik
authors.forename: Patrice
authors.initials: P
authors.lastname: Jichlinski
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use; D015607:Stents; D014570:Urologic Diseases / Q000175:diagnosis* / Q000628:therapy*
chemical_list: D000951:Antigens, Neoplasm; D009465:Neuromuscular Agents; C479341:prostate cancer antigen 3, human; D019274:Botulinum Toxins, Type A